PLCG2 and Alzheimer disease: Although pieces of evidence have shown that PLCγ2 may be a potential target protein for AD therapy (Magno et al., 2019; Magno et al., 2021; Maguire et al., 2021), the application of these methods in clinical practice is not feasible due to the current lack of effective inhibitors or activators of PLCγ2.